BRCA1 and triple-negative breast carcinoma: We previously reported results of the TNT trial that showed patients with a BRCA1/2 mutation and locally advanced/metastatic triple-negative breast cancer (TNBC) had improved response to carboplatin compared with docetaxel, with no significant selective benefit for carboplatin observed in the unselected population or those subcategorized by BRCA1 methylation, HRD status, or basal-like subtype (1).